TME Pharma N.V. (ALTME)
Market Closed
10 Aug, 15:30
XPAR 
€
0. 06
+0
+1.44%
€
6.25M Market Cap
- P/E Ratio
- Div Yield
95,977 Volume
- Eps
€ 0.06
Previous Close Want to track ALTME and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ALTME closed today higher at €0.06, an increase of 1.44% from yesterday's close, completing a monthly decrease of -15.4667% or -€0.01. Over the past 12 months, ALTME stock lost -6.7647%.
ALTME is not paying dividends to its shareholders.
The last earnings report, released on Oct 30, 2025, missed the consensus estimates by -0.02%. On average, the company has fell short of earnings expectations by -0.0067%, based on the last three reports.
TME Pharma N.V. has completed 3 stock splits, with the recent split occurring on Dec 10, 2024.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on XMUN (EUR).
TME Pharma N.V. (ALTME) FAQ
What is the stock price today?
The current price is €0.06.
On which exchange is it traded?
TME Pharma N.V. is listed on XPAR.
What is its stock symbol?
The ticker symbol is ALTME.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 6.25M.
Has TME Pharma N.V. ever had a stock split?
TME Pharma N.V. had 3 splits and the recent split was on Dec 10, 2024.
TME Pharma N.V. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Aram Mangasarian M.B.A., Ph.D. CEO | XPAR Exchange | NL0012044762 ISIN |
| DE Country | 12 Employees | - Last Dividend | 28 Jul 2022 Last Split | - IPO Date |
Overview
TME Pharma N.V. is a clinical-stage biopharmaceutical company dedicated to revolutionizing cancer treatment through its innovative research and development in Germany. As a pioneer in the field, it leverages the Spiegelmer platform to craft proprietary therapeutics aimed at combatting various forms of cancer. The company, initially known as NOXXON Pharma N.V., underwent a rebranding to TME Pharma N.V. in July 2022, reflecting its focused direction and ambition in the oncology space. Founded in 1997 and with its headquarters in Berlin, Germany, TME Pharma has positioned itself as a key player in the cancer research industry, emphasizing the development of combination therapies for a range of cancer indications.
Products and Services
- NOX-A12 - A lead cancer drug candidate designed by TME Pharma N.V., NOX-A12 is at the forefront of the company’s pipeline. It is currently under development as a combination therapy aimed at targeting various cancer indications, including metastatic pancreatic and colorectal cancer, as well as glioblastoma. This innovative therapeutic approach highlights TME Pharma's commitment to addressing hard-to-treat cancers and improving patient outcomes through combination therapy strategies.
- NOX-E36 - Another significant product candidate from TME Pharma N.V. is NOX-E36, which has successfully completed a Phase 1/2a clinical trial. This drug candidate is being developed for the treatment of diabetic nephropathy, showcasing the company's versatile approach not only in oncology but also in addressing complex metabolic disorders like diabetes. NOX-E36 represents TME Pharma's dedication to expanding its therapeutic pipeline beyond cancer, providing hope for patients with diabetic nephropathy.
Contact Information
Address: Max-Dohrn-Strasse 8-10, Berlin, Germany, 10589
Phone: 49 30 16637082 0
Website: https://www.tmepharma.com
